Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors
Blockade of the renin-angiotensin system (RAS) is well recognized as an essential therapy in hypertensive, heart, and kidney diseases. There are several classes of drugs that block the RAS; these drugs are known to exhibit antifibrotic action. An analysis of the molecular mechanisms of action for th...
Main Authors: | Kanasaki, Megumi, Nagai, Takako, Kitada, Munehiro, Koya, Daisuke, Kanasaki, Keizo |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2011
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253677/ |
Similar Items
-
Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis
by: Srivastava, Swayam Prakash, et al.
Published: (2016) -
N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
by: Kanasaki, Keizo, et al.
Published: (2014) -
N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition
by: Nagai, Takako, et al.
Published: (2014) -
Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen
by: Nitta, Kyoko, et al.
Published: (2016) -
N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice
by: Chan, Gary C. W., et al.
Published: (2015)